期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.688377
关键词
pancreatic cancer; chemotherapy; radiation; surgery; immunotherapy; targeted therapy; treatment
类别
资金
- Veterans Affairs Merit Award [I01BX004903, IK6 BX004855, I01BX002922]
- NIH [R01CA07059, F30CA236031, R01CA242003, R01CA217907, R21CA255291]
- UIC Award for Graduate Research
- Joseph and Ann Matella Fund for Pancreatic Cancer Research
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis, mainly due to late diagnosis, multi-drug resistance, and associated toxicities of chemotherapy. Current treatments are not very effective, highlighting the need to improve understanding of factors limiting efficacy in order to enhance patient survival and quality of life.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival time of 10-12 months. Clinically, these poor outcomes are attributed to several factors, including late stage at the time of diagnosis impeding resectability, as well as multi-drug resistance. Despite the high prevalence of drug-resistant phenotypes, nearly all patients are offered chemotherapy leading to modest improvements in postoperative survival. However, chemotherapy is all too often associated with toxicity, and many patients elect for palliative care. In cases of inoperable disease, cytotoxic therapies are less efficacious but still carry the same risk of serious adverse effects, and clinical outcomes remain particularly poor. Here we discuss the current state of pancreatic cancer therapy, both surgical and medical, and emerging factors limiting the efficacy of both. Combined, this review highlights an unmet clinical need to improve our understanding of the mechanisms underlying the poor therapeutic responses seen in patients with PDAC, in hopes of increasing drug efficacy, extending patient survival, and improving quality of life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据